RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Pulmonary Drug Delivery: Pharmaceutical Chemistry and Aerosol Technology
Pharmaceutical Chemistry and Aerosol Technology (Chapter 10)
Hickey, A. (2016). Pulmonary Drug Delivery: Pharmaceutical Chemistry and Aerosol Technology: Pharmaceutical Chemistry and Aerosol Technology (Chapter 10). In B. Wang, L. Hu, & TJ. Siahaan (Eds.), Drug Delivery: Principles and Applications, Second Edition (pp. 186-206). John Wiley & Sons, Inc.. https://doi.org/10.1002/9781118833322.ch10
Delivery of drugs as aerosols to the lungs requires consideration of a number of disciplines including physical chemistry, device design and engineering, aerosol physics, and involves physiological/anatomical and pharmacological strategies. The devices that are employed to deliver drugs to the lungs may be divided into three categories: propellant-driven metered-dose inhalers (pMDIs), dry powder inhalers (DPIs), and nebulizers. Each of these systems delivers aerosols by a different principle, and the chemistry associated with the product varies significantly between them. As it becomes increasingly probable that delivery of drugs as aerosols can be achieved readily, the focus can shift to the nature of the therapeutic agent and its physical and chemical stability in the dosage forms. New chemical entities can be considered for delivery to the lungs to facilitate the control of pulmonary diseases or disease that may be treated by pulmonary drug delivery.